VIATRIS INC. Payments to Noncontrolling Interests
VIATRIS INC. (VTRS) reported Payments to Noncontrolling Interests of $279.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaymentsToMinorityShareholders · last filed 2026-08-06
- VIATRIS INC. payments to noncontrolling interests for the quarter ending 2026-06-30 was $139.80M, a 0.00% change year-over-year.
- VIATRIS INC. payments to noncontrolling interests for the quarter ending 2026-03-31 was $139.60M, a 2.58% decline year-over-year.
- VIATRIS INC. payments to noncontrolling interests for the quarter ending 2025-12-31 was $138.20M, a 3.56% decline year-over-year.
- VIATRIS INC. payments to noncontrolling interests for the quarter ending 2025-09-30 was $139.90M, a 2.30% decline year-over-year.
- VIATRIS INC. payments to noncontrolling interests for fiscal 2025 was $561.20M, a 2.37% decline from fiscal 2024.
- VIATRIS INC. payments to noncontrolling interests for fiscal 2024 was $574.80M, a 0.14% decline from fiscal 2023.
- VIATRIS INC. payments to noncontrolling interests for fiscal 2023 was $575.60M, a 1.03% decline from fiscal 2022.
- VIATRIS INC. payments to noncontrolling interests for fiscal 2022 was $581.60M, a 45.76% increase from fiscal 2021.
| Period end | Payments to Noncontrolling Interests 3 month | Payments to Noncontrolling Interests 6 month | Payments to Noncontrolling Interests 9 month | Payments to Noncontrolling Interests 12 month |
|---|---|---|---|---|
| 2026-06-30 | $139.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $279.40M 10-Q · filed 2026-08-06 | $417.60M derived: sum of 3 quarters · filed 2026-08-06 | $557.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $139.60M 10-Q · filed 2026-05-07 | $277.80M derived: sum of 2 quarters · filed 2026-05-07 | $417.70M derived: sum of 3 quarters · filed 2026-05-07 | $557.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $138.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $278.10M derived: sum of 2 quarters · filed 2026-02-26 | $417.90M derived: sum of 3 quarters · filed 2026-08-06 | $561.20M 10-K · filed 2026-02-26 |
| 2025-09-30 | $139.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $279.70M derived: sum of 2 quarters · filed 2026-08-06 | $423.00M 10-Q · filed 2025-11-06 | $566.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $139.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $283.10M 10-Q · filed 2026-08-06 | $426.40M derived: sum of 3 quarters · filed 2026-08-06 | $569.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $143.30M 10-Q · filed 2026-05-07 | $286.60M derived: sum of 2 quarters · filed 2026-05-07 | $429.80M derived: sum of 3 quarters · filed 2026-05-07 | $575.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $143.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $286.50M derived: sum of 2 quarters · filed 2026-02-26 | $432.00M derived: sum of 3 quarters · filed 2026-02-26 | $574.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $143.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $288.70M derived: sum of 2 quarters · filed 2025-11-06 | $431.50M 10-Q · filed 2025-11-06 | $575.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $145.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $288.30M 10-Q · filed 2025-08-07 | $432.30M derived: sum of 3 quarters · filed 2026-02-26 | $576.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $142.80M 10-Q · filed 2025-05-08 | $286.80M derived: sum of 2 quarters · filed 2026-02-26 | $430.70M derived: sum of 3 quarters · filed 2026-02-26 | $574.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $144.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $287.90M derived: sum of 2 quarters · filed 2026-02-26 | $431.80M derived: sum of 3 quarters · filed 2026-02-26 | $575.60M 10-K · filed 2026-02-26 |
| 2023-09-30 | $143.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $287.80M derived: sum of 2 quarters · filed 2024-11-07 | $431.60M 10-Q · filed 2024-11-07 | $577.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $143.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $287.70M 10-Q · filed 2024-08-08 | $433.20M derived: sum of 3 quarters · filed 2025-02-27 | $578.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $143.80M 10-Q · filed 2024-05-09 | $289.30M derived: sum of 2 quarters · filed 2025-02-27 | $434.80M derived: sum of 3 quarters · filed 2025-02-27 | $580.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $145.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $291.00M derived: sum of 2 quarters · filed 2025-02-27 | $436.50M derived: sum of 3 quarters · filed 2025-02-27 | $581.60M 10-K · filed 2025-02-27 |
| 2022-09-30 | $145.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $291.00M derived: sum of 2 quarters · filed 2023-11-08 | $436.10M 10-Q · filed 2023-11-08 | $569.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $145.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $290.60M 10-Q · filed 2023-08-07 | $423.60M derived: sum of 3 quarters · filed 2024-02-28 | $556.60M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $145.10M 10-Q · filed 2023-05-08 | $278.10M derived: sum of 2 quarters · filed 2024-02-28 | $411.10M derived: sum of 3 quarters · filed 2024-02-28 | $544.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $133.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $266.00M derived: sum of 2 quarters · filed 2024-02-28 | $399.00M derived: sum of 3 quarters · filed 2024-02-28 | $399.00M 10-K · filed 2024-02-28 |
| 2021-09-30 | $133.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $266.00M derived: sum of 2 quarters · filed 2022-11-07 | $266.00M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $133.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $133.00M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $600.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |